{
    "medicine_id": "10d063bb47274ddecf197c7a65921ea7608487cd",
    "platform_id": "DB09098",
    "metadata": {
        "name": "Protropin Kit Im Sc 10mg vial Powder for solution",
        "composition": "Somatrem",
        "clinical_particulars": {
            "therapeutic_indications": "Somatrem is a recombinant human growth hormone indicated for a treatment of paediatric patients with growth failure due to growth hormone deficiency GHD b treatment of paediatric patients with growth failure due to idiopathic short stature ISS c treatment of paediatric patients with growth failure due to Turner syndrome TS d treatment of paediatric patients with growth failure due to chronic kidney disease CKD up to the time of renal transplantation e treatment of adults with childhood onset GHD or f treatment of adults with adult onset GHD FDA Label",
            "contraindications": {
                "disease": "Short term overdosage with somatrem may initially result in hypoglycaemia and then subsequently to hyperglycemia L1896 FDA Label Moreover this kind of short term overdosage with somatrem is also likely to cause fluid retention L1896 FDA Label Long term overdose with somatrem could leads to signs and symptoms of gigantism and or acromegaly consistent with the known effects of excess growth hormone L1896 FDA Label Some animal based oral LD50 values have been reported as mouse 300mg kg rabbit 3200 mg kg rat 980 mg kg",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In vitro and in vivo preclinical and clinical testing have demonstrated that somatrem is therapeutically equivalent to pituitary derived human growth hormone hGH L1896 FDA Label Paediatric patients who lack adequate endogenous growth hormone secretion patients with chronic kidney disease and patients with Turner syndrome that were treated with somatrem resulted in an increase in growth rate and an increase in insulin like growth factor IGF 1 levels similar to that seen with patients who possess endogenous pituitary derived hGH L1896 FDA Label With normalized levels of growth hormone and related mediator agents like IGF 1 patients demonstrate normalized skeletal cell organ and overall tissue growth L1896 FDA Label",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB01380",
                        "description": "The serum concentration of the active metabolites of Cortisone acetate can be reduced when Cortisone acetate is used in combination with Somatrem resulting in a loss in efficacy"
                    },
                    {
                        "drugbank-id": "DB13074",
                        "description": "The therapeutic efficacy of Macimorelin can be decreased when used in combination with Somatrem"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}